Kura Oncology, Inc. (KURA) DCF Valuation

Kura Oncology, Inc. (KURA) DCF Valuation
  • ✓ Entièrement Modifiable: Adapté À Vos Besoins Dans Excel Ou Sheets
  • ✓ Conception Professionnelle: Modèles Fiables Et Conformes Aux Normes Du Secteur
  • ✓ Pré-Construits Pour Une Utilisation Rapide Et Efficace
  • ✓ Aucune Expertise N'Est Requise; Facile À Suivre

Kura Oncology, Inc. (KURA) Bundle

DCF model
Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

Gain insights into your Kura Oncology, Inc. (KURA) valuation analysis using our sophisticated DCF Calculator! Preloaded with actual (KURA) data, this Excel template enables you to adjust forecasts and assumptions to determine Kura Oncology's intrinsic value with accuracy.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -67.5 -91.7 -129.7 -139.1 -165.0 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 .2 .6 .8 .8 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -67.5 -91.9 -130.3 -139.9 -165.8 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 236.9 633.3 518.0 438.0 424.0 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .0 .0
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable 3.5 2.8 3.2 1.5 2.3 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 -2.2 -1.1 -.6 -.2 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -67.5 -91.7 -129.7 -140.1 -165.8 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -64.0 -94.4 -129.8 -141.7 -164.4 -2.3 .0 .0 .0 .0
WACC, % 8.51 8.51 8.51 8.51 8.51 8.51 8.51 8.51 8.51 8.51
PV UFCF
SUM PV UFCF -2.1
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -20
Equity Value 18
Diluted Shares Outstanding, MM 73
Equity Value Per Share 0.25

What You Will Receive

  • Pre-Filled Financial Model: Kura Oncology’s actual data facilitates accurate DCF valuation.
  • Full Forecast Control: Modify revenue growth, margins, WACC, and other essential parameters.
  • Instant Calculations: Real-time updates guarantee you see results as adjustments are made.
  • Investor-Ready Template: A polished Excel file crafted for professional-level valuation.
  • Customizable and Reusable: Designed for adaptability, enabling repeated use for in-depth forecasts.

Key Features

  • Real-Life KURA Data: Pre-filled with Kura Oncology’s historical financials and forward-looking projections.
  • Fully Customizable Inputs: Adjust revenue growth, margins, WACC, tax rates, and capital expenditures.
  • Dynamic Valuation Model: Automatic updates to Net Present Value (NPV) and intrinsic value based on your inputs.
  • Scenario Testing: Create multiple forecast scenarios to analyze different valuation outcomes.
  • User-Friendly Design: Simple, structured, and designed for professionals and beginners alike.

How It Works

  • Step 1: Download the prebuilt Excel template with Kura Oncology’s data included.
  • Step 2: Explore the pre-filled sheets and understand the key metrics.
  • Step 3: Update forecasts and assumptions in the editable yellow cells (WACC, growth, margins).
  • Step 4: Instantly view recalculated results, including Kura Oncology’s intrinsic value.
  • Step 5: Make informed investment decisions or generate reports using the outputs.

Why Choose Kura Oncology, Inc. (KURA)?

  • Innovative Solutions: Cutting-edge therapies designed to target cancer with precision.
  • Proven Expertise: A team of seasoned professionals dedicated to advancing oncology treatments.
  • Robust Pipeline: A diverse portfolio of drug candidates in various stages of development.
  • Commitment to Patients: Focused on improving outcomes and quality of life for cancer patients.
  • Strong Partnerships: Collaborations with leading research institutions and healthcare organizations.

Who Should Use This Product?

  • Individual Investors: Make informed decisions about buying or selling Kura Oncology stock (KURA).
  • Financial Analysts: Streamline valuation processes with ready-to-use financial models specific to Kura Oncology (KURA).
  • Consultants: Deliver professional valuation insights on Kura Oncology (KURA) to clients quickly and accurately.
  • Business Owners: Understand how biotech companies like Kura Oncology (KURA) are valued to guide your own strategy.
  • Finance Students: Learn valuation techniques using real-world data and scenarios related to Kura Oncology (KURA).

What the Template Contains

  • Pre-Filled DCF Model: Kura Oncology's financial data preloaded for immediate use.
  • WACC Calculator: Detailed calculations for Weighted Average Cost of Capital.
  • Financial Ratios: Evaluate Kura Oncology's profitability, leverage, and efficiency.
  • Editable Inputs: Change assumptions such as growth, margins, and CAPEX to fit your scenarios.
  • Financial Statements: Annual and quarterly reports to support detailed analysis.
  • Interactive Dashboard: Easily visualize key valuation metrics and results.

No products were found matching.